Epigenetic regulation and heart failure

Expert Review of Cardiovascular Therapy

Volumn 12, Issue 9, 2014, Pages 1087-1098

  Cao, Dian J ^a  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

DNA methylation; epigenetic; heart failure; histone modification; metabolic; mitochondria

Indexed keywords

CARDIOMYOPATHY; DIABETIC CARDIOMYOPATHY; DNA METHYLATION; DNA MODIFICATION; DNA SEQUENCE; DNA TRANSCRIPTION; EPIGENETICS; GENOMICS; HEART FAILURE; HISTONE ACETYLATION; HISTONE DEMETHYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; HOMEOSTASIS; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; REVIEW; ACETYLATION; ANIMAL; GENETIC EPIGENESIS; GENETICS; METABOLISM; PATHOPHYSIOLOGY;

HISTONE;

ACETYLATION; ANIMALS; DNA METHYLATION; EPIGENESIS, GENETIC; HEART FAILURE; HISTONES; HUMANS;

EID: 84906775466     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2014.942285     Document Type: Review

References (119)

1. Braunwald E. Heart failure. JCHF 2013; 1(1):1-20
2. Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for developing congestive heart failure: The Framingham Heart Study. Circulation 2002;106(24):3068-72
3. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2012 update: A report from the American Heart Association. Circulation 2012;125(1): E2-e220
4. Francis GS, Goldsmith SR, Levine TB, et al. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984;101(3): 370-7
5. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan. patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 2003;362(9386):777-81
6. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359(23):2456-67
7. Gilbert SF. Commentary: 'The epigenotype' by C.H. Waddington. Int J Epidemiol 2012;41(1):20-3
8. Riddihough G, Zahn LM. Epigenetics. What is epigenetics?. Introduction. Science 2010;330(6004):611
9. Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational definition of epigenetics. Genes Dev 2009;23(7):781-3
10. Dawson MA, Kouzarides T. Cancer epigenetics: From mechanism to therapy. Cell 2012;150(1):12-27
11. Goldberg AD, Allis CD, Bernstein E. Epigenetics: A landscape takes shape. Cell 2007;128(4):635-8
12. Jakovcevski M, Akbarian S. Epigenetic mechanisms in neurological disease. Nat Med 2012;18(8):1194-204
13. Dawson MA, Kouzarides T, Huntly BJ. Targeting epigenetic readers in cancer. N Engl J Med 2012;367(7):647-57
14. Barber MF, Michishita-Kioi E, Xi Y, et al. SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature 2012;487(7405):114-18
15. Wu H, Zhang Y. Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation. Genes Dev 2011; 25(23):2436-52
16. Tan M, Luo H, Lee S, et al. Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. Cell 2011;146(6):1016-28
17. Berger SL. The complex language of chromatin regulation during transcription. Nature 2007;447(7143):407-12
18. Govind CK, Zhang F, Qiu H, et al. Gcn5 promotes acetylation, eviction, and methylation of nucleosomes in transcribed coding regions. Mol Cell 2007;25(1):31-42
19. Vogelauer M, Wu J, Suka N, Grunstein M. Global histone acetylation and deacetylation in yeast. Nature 2000;408(6811):495-8
20. Kimura H. Histone modifications for human epigenome analysis. J Human Genet 2013;58(7):439-45
21. Schones DE, Cui K, Cuddapah S, et al. Dynamic regulation of nucleosome positioning in the human genome. Cell 2008;132(5):887-98
22. McKinsey TA, Zhang CL, Lu J, Olson EN. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature 2000;408(6808):106-11
23. Wei JQ, Shehadeh LA, Mitrani JM, et al. Quantitative control of adaptive cardiac hypertrophy by acetyltransferase p300. Circulation 2008;118(9):934-46
24. Zhang CL, McKinsey TA, Chang S, et al. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002;110(4):479-88
25. Cao DJ, Wang ZV, Battiprolu PK, et al. Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy. Proc Natl Acad Sci USA 2011;108(10):4123-8
26. Li HL, Liu C, De Couto G, et al. Curcumin prevents and reverses murine cardiac hypertrophy. J Clin Invest 2008; 118(3):879-93
27. Yao TP, Oh SP, Fuchs M, et al. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 1998; 93(3):361-72
28. Gusterson RJ, Jazrawi E, Adcock IM, Latchman DS. The transcriptional co-Activators CREB-binding protein (CBP) and p300 play a critical role in cardiac hypertrophy that is dependent on their histone acetyltransferase activity. J Biol Chem 2003;278(9):6838-47
29. Miyamoto S, Kawamura T, Morimoto T, et al. Histone acetyltransferase activity of p300 is required for the promotion of left ventricular remodeling after myocardial infarction in adult mice in vivo. Circulation 2006;113(5):679-90
30. Backs J, Olson EN. Control of cardiac growth by histone acetylation/deacetylation. Circ Res 2006;98(1):15-24
31. Michishita E, Park JY, Burneskis JM, et al. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell 2005; 16(10):4623-35
32. Mostoslavsky R, Chua KF, Lombard DB, et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 2006;124(2):315-29
33. Montgomery RL, Davis CA, Potthoff MJ, et al. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev 2007;21(14):1790-802
34. Trivedi CM, Luo Y, Yin Z, et al. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med 2007;13(3):324-31
35. Lehmann LH, Worst BC, Stanmore DA, Backs J. Histone deacetylase signaling in cardioprotection. Cell Mole Life Sci 2014; 71(9):1673-90
36. Chang S, McKinsey TA, Zhang CL, et al. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 2004; 24(19):8467-76
37. Chang S, Young BD, Li S, et al. Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 2006;126(2):321-34
38. Vega RB, Matsuda K, Oh J, et al. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 2004;119(4):555-66
39. Kawahara TL, Michishita E, Adler AS, et al. SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell 2009;136(1):62-74
40. Schwer B, Schumacher B, Lombard DB, et al. Neural sirtuin 6 (Sirt6) ablation attenuates somatic growth and causes obesity. Proc Natl Acad Sci USA 2010; 107(50):21790-4
41. Sundaresan NR, Vasudevan P, Zhong L, et al. The sirtuin SIRT6 blocks IGF-Akt signaling and development of cardiac hypertrophy by targeting c-Jun. Nat Med 2012;18(11):1643-50
42. Vakhrusheva O, Smolka C, Gajawada P, et al. Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. Circ Res 2008;102(6):703-10
43. Hafner AV, Dai J, Gomes AP, et al. Regulation of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 166 suppresses age-related cardiac hypertrophy. Aging 2010;2(12):914-23
44. Antos CL, McKinsey TA, Dreitz M, et al. Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J Biol Chem 2003;278(31): 28930-7
45. Ferguson BS, Harrison BC, Jeong MY, et al. Signal-dependent repression of DUSP5 by class I HDACs controls nuclear ERK activity and cardiomyocyte hypertrophy. Proc Natl Acad Sci USA 2013;110(24):9806-11
46. Kee HJ, Sohn IS, Nam KI, et al. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation 2006;113(1):51-9
47. Kong Y, Tannous P, Lu G, et al. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 2006;113(22): 2579-88
48. Papait R, Cattaneo P, Kunderfranco P, et al. Genome-wide analysis of histone marks identifying an epigenetic signature of promoters and enhancers underlying cardiac hypertrophy. Proc Natl Acad Sci USA 2013;110(50):20164-9
49. Cheung P, Lau P. Epigenetic regulation by histone methylation and histone variants. Mol Endocrinol 2005;19(3):563-73
50. Rea S, Eisenhaber F, O'Carroll D, et al. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 2000;406(6796):593-9
51. Greer EL, Shi Y. Histone methylation: A dynamic mark in health, disease and inheritance. Nat Rev Genet 2012;13(5): 343-57
52. Shi Y, Lan F, Matson C, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004; 119(7):941-53
53. Kooistra SM, Helin K. Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol 2012;13(5):297-311
54. Bannister AJ, Kouzarides T. Histone methylation: Recognizing the methyl mark. Methods Enzymol 2004;376:269-88
55. Vermeulen M, Mulder KW, Denissov S, et al. Selective anchoring of TFIID to nucleosomes by trimethylation of histone H3 lysine 4. Cell 2007;131(1):58-69
56. LeRoy G, Rickards B, Flint SJ. The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription. Mol cell 2008;30(1):51-60
57. Probst AV, Almouzni G. Heterochromatin establishment in the context of genome-wide epigenetic reprogramming. Trends Genet 2011;27(5):177-85
58. Nozawa RS, Nagao K, Masuda HT, et al. Human POGZ modulates dissociation of HP1a from mitotic chromosome arms through Aurora B activation. Nat Cell Biol 2010;12(7):719-27
59. Kaneda R, Takada S, Yamashita Y, et al. Genome-wide histone methylation profile for heart failure. Genes Cells 2009;14(1): 69-77
60. Movassagh M, Vujic A, Foo R. Genome-wide DNA methylation in human heart failure. Epigenomics 2011;3(1):103-9
61. Movassagh M, Choy MK, Knowles DA, et al. Distinct epigenomic features in end-stage failing human hearts. Circulation 2011;124(22):2411-22
62. Turner BM. Defining an epigenetic code. Nat Cell Biol 2007;9(1):2-6
63. Ruthenburg AJ, Allis CD, Wysocka J. Methylation of lysine 4 on histone H3: Intricacy of writing and reading a single epigenetic mark. Mol Cell 2007;25(1):15-30
64. Stein AB, Jones TA, Herron TJ, et al. Loss of H3K4 methylation destabilizes gene expression patterns and physiological functions in adult murine cardiomyocytes. J Clin Invest 2011;121(7):2641-50
65. Kuo HC, Cheng CF, Clark RB, et al. A defect in the Kv channel-interacting protein 2 (KChIP2) gene leads to a complete loss of I(to) and confers susceptibility to ventricular tachycardia. Cell 2001;107(6):801-13
66. Radicke S, Cotella D, Graf EM, et al. Functional modulation of the transient outward current Ito by KCNE beta-subunits and regional distribution in human non-failing and failing hearts. Cardiovasc Res 2006;71(4):695-703
67. Pandya K, Kohro T, Mimura I, et al. Distribution of histone3 lysine 4 trimethylation at T3-responsive loci in the heart during reversible changes in gene expression. Gene Expr 2012;15(4):183-98
68. Zhang QJ, Chen HZ, Wang L, et al. The histone trimethyllysine demethylase JMJD2A promotes cardiac hypertrophy in response to hypertrophic stimuli in mice. J Clin Invest 2011;121(6):2447-56
69. Xing W, Zhang TC, Cao D, et al. Myocardin induces cardiomyocyte hypertrophy. Circ Res 2006;98(8):1089-97
70. Feng Q, Wang H, Ng HH, et al. Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr Biol 2002;12(12):1052-8
71. Ng HH, Feng Q, Wang H, et al. Lysine methylation within the globular domain of histone H3 by Dot1 is important for telomeric silencing and Sir protein association. Genes Dev 2002;16(12): 1518-27
72. Barski A, Cuddapah S, Cui K, et al. High-resolution profiling of histone methylations in the human genome. Cell 2007;129(4):823-37
73. Schubeler D, MacAlpine DM, Scalzo D, et al. The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote. Genes Dev 2004;18(11):1263-71
74. Steger DJ, Lefterova MI, Ying L, et al. DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells. Mol Cell Biol 2008;28(8): 2825-39
75. Jones B, Su H, Bhat A, et al. The histone H3K79 methyltransferase Dot1L is essential for mammalian development and heterochromatin structure. PLoS Genet 2008;4(9):e1000190
76. Nguyen AT, Xiao B, Neppl RL, et al. DOT1L regulates dystrophin expression and is critical for cardiac function. Genes Dev 2011;25(3):263-74
77. Seidman JG, Seidman C. The genetic basis for cardiomyopathy: From mutation identification to mechanistic paradigms. Cell 2001;104(4):557-67
78. Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 2007;447(7143): 425-32
79. Lister R, Pelizzola M, Dowen RH, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009;462(7271):315-22
80. Ziller MJ, Gu H, Muller F, et al. Charting a dynamic DNA methylation landscape of the human genome. Nature 2013; 500(7463):477-81
81. Smith ZD, Meissner A. DNA methylation: Roles in mammalian development. Nat Rev Genet 2013;14(3):204-20
82. Irizarry RA, Ladd-Acosta C, Wen B, et al. The human colon cancer methylome shows similar hypo-And hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009;41(2):178-86
83. Campbell RM, Tummino PJ. Cancer epigenetics drug discovery and development: The challenge of hitting the mark. J Clin Invest 2014;124(3):1419
84. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002;16(1): 6-21
85. Bergman Y, Cedar H. DNA methylation dynamics in health and disease. Nat Struct Mol Biol 2013;20(3):274-81
86. Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Dev 2011;25(10):1010-22
87. Laird PW, Jackson-Grusby L, Fazeli A, et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 1995;81(2): 197-205
88. Yamada Y, Jackson-Grusby L, Linhart H, et al. Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis. Proc Natl Acad Sci USA 2005;102(38):13580-5
89. Movassagh M, Choy MK, Goddard M, et al. Differential DNA methylation correlates with differential expression of angiogenic factors in human heart failure. PLoS One 2010;5(1):e8564
90. Haas J, Frese KS, Park YJ, et al. Alterations in cardiac DNA methylation in human dilated cardiomyopathy. EMBO Mol Med 2013;5(3):413-29
91. Schilling JD, Mann DL. Diabetic cardiomyopathy: Bench to bedside. Heart Fail Clin 2012;8(4):619-31
92. Konig A, Bode C, Bugger H. Diabetes mellitus and myocardial mitochondrial dysfunction: Bench to bedside. Heart Fail Clin 2012;8(4):551-61
93. Dhalla NS, Takeda N, Rodriguez-Leyva D, Elimban V. Mechanisms of subcellular remodeling in heart failure due to diabetes. Heart Fail Rev 2013
94. Goldberg IJ, Trent CM, Schulze PC. Lipid metabolism and toxicity in the heart. Cell Metab 2012;15(6):805-12
95. Krishnan KJ, Reeve AK, Samuels DC, et al What causes mitochondrial DNA deletions in human cells?. Nat Genet 2008;40(3): 275-9
96. Dorn GW 2nd. Mitochondrial dynamics in heart disease. Biochim Biophys Acta 2013; 1833(1):233-41
97. Goffart S, von Kleist-Retzow JC, Wiesner RJ. Regulation of mitochondrial proliferation in the heart: Power-plant failure contributes to cardiac failure in hypertrophy. Cardiovasc Res 2004;64(2): 198-207
98. Liu C, Lin JD. PGC-1 coactivators in the control of energy metabolism. Acta Biochim Biophys Sin (Shanghai) 2011;43(4):248-57
99. Hallberg BM, Larsson NG. TFAM forces mtDNA to make a U-Turn. Nat Struct Mol Biol 2011;18(11):1179-81
100. Bayeva M, Gheorghiade M, Ardehali H. Mitochondria as a therapeutic target in heart failure. J Am Coll Cardiol 2013;61(6): 599-610
101. Patti ME, Butte AJ, Crunkhorn S, et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc Natl Acad Sci USA 2003;100(14):8466-71
102. Csiszar A, Labinskyy N, Pinto JT, et al. Resveratrol induces mitochondrial biogenesis in endothelial cells. Am J Physiol Heart Circ Physiol 2009;297(1):H13-20
103. Rong JX, Qiu Y, Hansen MK, et al. Adipose mitochondrial biogenesis is suppressed in db/db and high-fat diet-fed mice and improved by rosiglitazone. Diabetes 2007;56(7):1751-60
104. Duncan JG, Fong JL, Medeiros DM, et al. Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator- Activated receptor-Alpha/PGC-1alpha gene regulatory pathway. Circulation 2007;115(7):909-17
105. Boudina S, Sena S, O'Neill BT, et al. Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation 2005;112(17):2686-95
106. Bugger H, Abel ED. Mitochondria in the diabetic heart. Cardiovasc Res 2010;88(2): 229-40
107. Schwenk RW, Vogel H, Schurmann A. Genetic and epigenetic control of metabolic health. Mol Metab 2013;2(4):337-47
108. Kirchner H, Osler ME, Krook A, Zierath JR. Epigenetic flexibility in metabolic regulation: Disease cause and prevention?. Trends Cell Biol 2013;23(5): 203-9
109. Ng SF, Lin RC, Laybutt DR, et al. Chronic high-fat diet in fathers programs beta-cell dysfunction in female rat offspring. Nature 2010;467(7318):963-6
110. McGee SL, Hargreaves M. Exercise and skeletal muscle glucose transporter 4 expression: Molecular mechanisms. Clin Exp Pharmacol Physiol 2006;33(4):395-9
111. Tateishi K, Okada Y, Kallin EM, Zhang Y. Role of Jhdm2a in regulating metabolic gene expression and obesity resistance. Nature 2009;458(7239):757-61
112. Barres R, Yan J, Egan B, et al. Acute exercise remodels promoter methylation in human skeletal muscle. Cell Metab 2012; 15(3):405-11
113. Barres R, Osler ME, Yan J, et al. Non-CpG methylation of the PGC-1alpha promoter through DNMT3B controls mitochondrial density. Cell Metab 2009;10(3):189-98
114. Villeneuve LM, Natarajan R. The role of epigenetics in the pathology of diabetic complications. Am J Physiol Renal Physiol 2010;299(1):F14-25
115. Shimazu T, Hirschey MD, Newman J, et al. Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 2013; 339(6116):211-14
116. Shyh-Chang N, Locasale JW, Lyssiotis CA, et al. Influence of threonine metabolism on S-Adenosylmethionine and histone methylation. Science 2013;339(6116):222-6
117. Galmozzi A, Mitro N, Ferrari A, et al. Inhibition of class I histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue. Diabetes 2013; 62(3):732-42
118. Mathiyalagan P, Keating ST, Du XJ, El-Osta A. Interplay of chromatin modifications and non-coding RNAs in the heart. Epigenetics 2013;9(1):101-12
119. Zhou S, Liu Y, Prater K, et al. Roles of microRNAs in pressure overload-And ischemia-related myocardial remodeling. Life Sci 2013;93(23):855-62.